Info

IDM Pharma, Inc. (IDM) is a biopharmaceutical company focused on the development of cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering an adaptive immune response. The Company’s principal product candidate, mifamurtide (L-MTP-PE), also called MEPACT in Europe, is part of a family of immunotherapeutic agents that activate the body’s natural defenses. L-MTP-PE activates macrophages in-vivo (inside the body), in order to enhance their ability to destroy cancer cells. As of December 31, 2007, it is developing L-MTP-PE for the treatment of osteosarcoma, the common type of bone cancer. L-MTP-PE has received orphan drug designation in the United States and the European Union for this indication, permitting it to benefit from a set of laws encouraging the development of treatments for rare diseases.(Source: 10-K)